73 related articles for article (PubMed ID: 26616436)
21. Mechanism of suppression of normal hemopoietic activity by lymphokine-activated killer cells and their products.
Gibson FM; Malkovska V; Myint AA; Meager A; Gordon-Smith EC
Exp Hematol; 1991 Aug; 19(7):659-63. PubMed ID: 1909968
[TBL] [Abstract][Full Text] [Related]
22. Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma.
Dillman RO; Duma CM; Ellis RA; Cornforth AN; Schiltz PM; Sharp SL; DePriest MC
J Immunother; 2009; 32(9):914-9. PubMed ID: 19816190
[TBL] [Abstract][Full Text] [Related]
23. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
24. Synergistic effect of Nocardia rubra cell wall skeleton and recombinant interleukin 2 for in vivo induction of lymphokine-activated killer cells.
Miyazaki K; Yasumoto K; Yano T; Matsuzaki G; Sugimachi K; Nomoto K
Cancer Res; 1991 Oct; 51(19):5261-5. PubMed ID: 1833049
[TBL] [Abstract][Full Text] [Related]
25. Differential modulation of surface antigens on human macrophages by IFN-gamma and GM-CSF: effect on susceptibility to LAK lysis.
Blanchard DK; Djeu JY
J Leukoc Biol; 1991 Jul; 50(1):28-34. PubMed ID: 1905335
[TBL] [Abstract][Full Text] [Related]
26. Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells.
Holladay FP; Heitz T; Wood GW
J Neurosurg; 1992 Nov; 77(5):757-62. PubMed ID: 1403119
[TBL] [Abstract][Full Text] [Related]
27. Isolation of human NK cells and generation of LAK activity.
Whiteside TL
Curr Protoc Immunol; 2001 May; Chapter 7():Unit 7.7. PubMed ID: 18432847
[TBL] [Abstract][Full Text] [Related]
28. Adhesion molecule-mediated signals regulate major histocompatibility complex-unrestricted and CD3/T cell receptor-triggered cytotoxicity.
Galandrini R; Albi N; Zarcone D; Grossi CE; Velardi A
Eur J Immunol; 1992 Aug; 22(8):2047-53. PubMed ID: 1379184
[TBL] [Abstract][Full Text] [Related]
29. Enhancement of lymphokine-activated killer cell induction using anti-CD25 and anti-CTLA-4 monoclonal antibodies.
Okita R; Yamaguchi Y; Emi A; Matsuura K; Toge T
Oncol Rep; 2007 Jun; 17(6):1429-35. PubMed ID: 17487401
[TBL] [Abstract][Full Text] [Related]
30. OK-432 develops CTL and LAK activity in mononuclear cells from regional lymph nodes of lung cancer patients.
Takahashi K; Harauchi D; Kimura S; Saito S; Monden Y
Int J Immunopharmacol; 1998 Aug; 20(8):375-88. PubMed ID: 9778099
[TBL] [Abstract][Full Text] [Related]
31. Cell cycle assessment of adoptive transferred lymphokine activated killer cells.
Watanabe R; Tanaka N; Naomoto Y; Moreira LF; Orita K
Jpn J Clin Oncol; 1994 Apr; 24(2):59-65. PubMed ID: 8158860
[TBL] [Abstract][Full Text] [Related]
32. Modulation of leukemic cell sensitivity to lymphokine-activated killer cytolysis: role of intercellular adhesion molecule-1.
Triozzi PL; Eicher DM; Smoot J; Rinehart JJ
Exp Hematol; 1992 Oct; 20(9):1072-6. PubMed ID: 1361453
[TBL] [Abstract][Full Text] [Related]
33. On the relative roles of interleukin-2 and interleukin-10 in the generation of lymphokine-activated killer cell activity.
Spagnoli GC; Juretic A; Schultz-Thater E; Dellabona P; Filgueira L; Hörig H; Zuber M; Garotta G; Heberer M
Cell Immunol; 1993 Feb; 146(2):391-405. PubMed ID: 8174177
[TBL] [Abstract][Full Text] [Related]
34. Induction of human monocyte susceptibility to lymphokine-activated killer cell lysis by granulocyte-macrophage colony-stimulating factor.
Blanchard DK; Serbousek D; Djeu JY
Cancer Res; 1989 Sep; 49(18):5037-43. PubMed ID: 2670200
[TBL] [Abstract][Full Text] [Related]
35. A high density cell culture system for generation of human lymphokine-activated killer (LAK) cells for clinical use in adoptive immunotherapy.
Shimizu K; Park K; Yamada M; Tarura K; Matsui Y; Hayakawa T
J Clin Lab Immunol; 1990 May; 32(1):41-7. PubMed ID: 1967036
[TBL] [Abstract][Full Text] [Related]
36. The role of lymphotoxin in the IL-2-driven differentiation of human lymphokine-activated T-killer (T-LAK) cells in vitro.
Abe Y; Van Eden M; Gatanaga M; Wang FI; Brightbill HD; Granger GA; Gatanaga T
Lymphokine Cytokine Res; 1993 Oct; 12(5):279-83. PubMed ID: 8260536
[TBL] [Abstract][Full Text] [Related]
37. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
38. GM-CSF enhances IL-2-activated natural killer cell lysis of clonogenic AML cells by upregulating target cell expression of ICAM-1.
Bendall LJ; Kortlepel K; Gottlieb DJ
Leukemia; 1995 Apr; 9(4):677-84. PubMed ID: 7723403
[TBL] [Abstract][Full Text] [Related]
39. Effect of local administration of lymphokine-activated killer cells and interleukin-2 on malignant brain tumor patients.
Ibayashi Y; Yamaki T; Kawahara T; Daibo M; Kubota T; Uede T; Tanabe S; Hashi K
Neurol Med Chir (Tokyo); 1993 Jul; 33(7):448-57. PubMed ID: 7692323
[TBL] [Abstract][Full Text] [Related]
40. Differential regulation of lymphokine production by distinct subunits of the T cell interleukin 2 receptor.
Burdach S; Zessack N; Dilloo D; Shatsky M; Thompson D; Levitt L
J Clin Invest; 1991 Jun; 87(6):2114-21. PubMed ID: 1828253
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]